Melphalan, Yttrium Y 90 Ibritumomab Tiuxetan, and Rituximab Followed by Autologous Stem Cell Transplant in Treating Older Patients With Non-Hodgkin's Lymphoma That Has Relapsed or Not Responded to Previous Treatment
Swiss Cancer Institute
Swiss Cancer Institute
Wake Forest University Health Sciences
Case Comprehensive Cancer Center
National Cancer Institute (NCI)
Northwestern University
National Institutes of Health Clinical Center (CC)
Mayo Clinic